Skip to content
DraconiticResearch
Search Sources API
211,646 studies31 sourcesUpdated 43 min ago

Oncology

5,331 studies510 in 7 days2,567 in 30 days

Filters
Type
Date
Clear

Latest

5,331 studies

  1. Factors Associated with Patient Interest in a Digital Exercise and Mind–Body Program for Patients Undergoing Active Cancer Treatment: A Secondary Analysis of a Randomized Clinical Trial
    Karolina Bryl, Esin Namoglu, Susan Chimonas +4
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Rethinking Age Limits for Robotic Lung Cancer Resection: Contemporary Short-Term Outcomes in Octogenarians
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Therapy-Induced Senescence in Cancer Treatment Resistance: Mechanisms, Evidence, and Translational Opportunities
    Jose-Ramon Blanco, Amancio Carnero
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. From Innovation to Underutilization: Why Chest Wall Perforator Flaps Have Not Achieved Widespread Adoption—Insights from the Literature and a High-Volume Single-Center Cohort
    Theodoros Kontoulis, Panagiota Koutra
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  6. Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data
    Hee Sung Kim, Kyoung Eun Yeob, So Young Kim +2
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  7. Twenty-Five Years of Colorectal Cancer Screening in the Czech Republic: National Registry Trends in Program Performance and Cancer Burden
    Stepan Suchanek, Monika Ambrozova, Tomas Grega +7
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  8. Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction
    Emmanuel Massy, Nicolas Stacoffe, Fauvernier, M. +12
    Journal of Bone OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyHAL
  9. A unique malignant cell type per patient tumor encoded in each cancer cell transcriptome
    Mirca S Saurty-Seerunghen, Elias A El-Habr, Yossi Eliaz +4
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textOncologyHAL
  10. Identification of dual-targeting PROTACs for ataxia telangiectasia and RAD3-related and aurora kinase A as chemo-sensitizers for leukemia cells
    Abdallah M Alfayomy, Sarah Neuroth, Anne-Christin Sarnow +9
    European Journal of Medicinal ChemistryPeer-reviewedCC BY 4.0Full textOncologyHAL
  11. Pt(II)-Flavin Complexes As Anticancer And Antibacterial Agents
    Maria Jesus Moran Plata, Igor V. Esarev, Nitin Kumar +8
    ChemRxivPreprintCC BYFull textOncologyChemRxiv
  12. ATM inhibition attenuates ferroptosis-associated injury and reduces infarct volume in experimental stroke
    Han Kyu Lee, Chao-Chieh Lin, Denise E. Dunn +5
    Ferroptosis and oxidative stressPeer-reviewedCC BY 4.0Full textOncologyPMC
  13. Integrative network toxicology and transcriptomic analyses identify DCP1B and HAS2 as key prognostic biomarkers in formaldehyde-associated Wilms tumor
    Gui Jun Li, Sheng Zhang, Li Na Chang +3
    The Journal of International Medical ResearchPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  14. Impact of Clinicopathologic Factors on Breast Cancer Diagnosed in Pregnancy
    Malcolm Su, Diti Patel, Samira Syed +5
    OncologyPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  15. Mitochondrial priming in human germ cell tumors is dependent on MCL1 and BCL2L1
    S. Anniko, S. Khan, J. R. Morton +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  16. A platform for deep topographic multiomic mapping of the bone marrow environment in multiple myeloma
    J. Lu, C.-Y. Wang, S. Davis +22
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  17. Cancer-associated nucleolar morphological changes coincide with altered subcompartment organization and accelerated nascent rRNA trafficking in breast cancer cells
    K. Fan, W. Wang, G. Kipkemoi +3
    bioRxivPreprintCC BYFull textOncologybioRxiv
  18. Chemical Proteomics of Residual Acute Myeloid Leukemia Cells Reveals Therapeutic Vulnerabilities
    E. Gholizadeh, U. Vadadokhau, M. Varli +11
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  19. MMRi62 induces iron depletion-driven apoptosis through a ferritin-independent mechanism
    F. Segui, M. Pagnuzzi, J. Antiq +6
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  20. Activation of vitamin D signaling suppresses platinum-induced ovarian cancer stem cell plasticity
    T. X. Metcalfe, S. Xanders, R. A. Kinne +6
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  21. Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells
    R. Prakash, B. Forgie, A. A. Goyeneche +4
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  22. Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer
    S. Zhang, Z. Fu, Y. Zhou +6
    bioRxivPreprintCC BYFull textOncologybioRxiv
  23. Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response
    X. Tian, P. Srinivasan, W. S. El-Deiry
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  24. Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance
    J. Yoo, Y.-N. Kim, Y. Jung +4
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  25. Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.
    J-S Frenel, A Gonçalves, J Quintin +10
    ESMO real world data and digital oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC